Intercurrent infection as a risk factor for disease flares in patients with systemic lupus erythematosus

Autor: Alexandre E Voskuyl, Irene E M Bultink, Birgit I Lissenberg-Witte, Michel W P Tsang-A-Sjoe, Fatma el Hadiyen

Publikováno v: Lupus Science and Medicine, Vol 11, Iss 2 (2024)

Objective To determine whether intercurrent infections are a risk factor for subsequent disease flares in systemic lupus erythematosus (SLE).Methods Demographic and clinical characteristics of 203 patients with SLE participating in the Amsterdam SLE

Externí odkaz: https://doaj.org/article/949bcb1d1e6c45f69d383363790ab0d9

Hydroxychloroquine treatment in European patients with lupus erythematosus: dosing, retinopathy screening and adherence

Autor: Zgjim Osmani, Thijs J Schrama, Wendy Zacouris-Verweij, Susan Frankel, Irene E M Bultink

Publikováno v: Lupus Science and Medicine, Vol 8, Iss 1 (2021)

Background Use of hydroxychloroquine (HCQ) is common in patients with lupus erythematosus. Long-term use (ie, ≥5 years) and high-dose HCQ (ie, >5 mg/kg/day) are both risk factors for developing HCQ retinopathy. Advances in our understanding of HCQ

Externí odkaz: https://doaj.org/article/5c6902dcd0774285bf8049de1ed8710a

Maternal and Perinatal Outcome in Women with Systemic Lupus Erythematosus: A Retrospective Bicenter Cohort Study

Autor: Sylvia J. Kroese, Carolien N. H. Abheiden, Birgit S. Blomjous, Jacob M. van Laar, Ronald W. H. M. Derksen, Irene E. M. Bultink, Alexandre E. Voskuyl, A. Titia Lely, Marjon A. de Boer, Johanna I. P. de Vries, Ruth D. E. Fritsch-Stork

Publikováno v: Journal of Immunology Research, Vol 2017 (2017)

Objective. To investigate disease activity around and during pregnancy and pregnancy outcome in women with systemic lupus erythematosus (SLE) considering antiphospholipid antibody status. Moreover, differences between first and consecutive pregnancie

Externí odkaz: https://doaj.org/article/b27c7ed42ac04b75b71d22159bff198f

Early predictors of renal outcome in patients with proliferative lupus nephritis: a 36-month cohort study

Autor: José António Pereira da Silva, Alexandre E Voskuyl, Luís Inês, Mariana Luís, Irene E. M. Bultink

Publikováno v: Rheumatology (Oxford, England), 60(11), 5134-5141. Oxford University Press
Luís, M S F, Bultink, I E M, da Silva, J A P, Voskuyl, A E & Inês, L S 2021, ' Early predictors of renal outcome in patients with proliferative lupus nephritis : a 36-month cohort study ', Rheumatology (Oxford, England), vol. 60, no. 11, pp. 5134-5141 . https://doi.org/10.1093/rheumatology/keab126, https://doi.org/10.1093/rheumatology/keab126

Objectives To identify predictors of complete renal response (CRR) and renal flares in SLE patients with active proliferative LN. Methods This was a retrospective cohort study over 36 months including patients with biopsy-proven proliferative LN (cla

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f7d24735ac8935fe226aeca77d16f514
https://doi.org/10.1093/rheumatology/keab126

Long-term effects on bone mineral density after four years of treatment with two intensive combination strategies, including initially high-dose prednisolone, in early rheumatoid arthritis patients: the COBRA-light trial

Autor: Willem F. Lems, Irene E. M. Bultink, Pit J S M Kerstens, M. T. Nurmohamed, D. den Uyl, D. van Schaardenburg, Alexandre E. Voskuyl, Maarten Boers, N. P. C. Konijn, M. M. ter Wee, M. J. J. Lucassen

Publikováno v: Lucassen, M J J, ter Wee, M, den Uyl, D, Konijn, NPC, Nurmohamed, MT, Voskuyl, AE, van Schaardenburg, D, Kerstens, P J S M, Bultink, IEM, Boers, M & Lems, WF 2021, ' Long-term effects on bone mineral density after four years of treatment with two intensive combination strategies, including initially high-dose prednisolone, in early rheumatoid arthritis patients: the COBRA-light trial ', Osteoporosis International, vol. 32, no. 7, 10.1007/s00198-020-05781-7, pp. 1441-1449 . https://doi.org/10.1007/s00198-020-05781-7
Osteoporosis International
Osteoporosis international, 32(7), 1441-1449. Springer London
Osteoporosis International, 32(7):10.1007/s00198-020-05781-7, 1441-1449. Springer London

Summary In this study, no difference in bone loss was observed between patients with early RA initially treated with COmbinatietherapie Bij Reumatoide Artritis (COBRA) (including initially 60 mg/day prednisolone) and patients treated with COBRA-light

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d0a3c21f72884df3ebc9379b3d50c23
https://research.vumc.nl/en/publications/8acfa484-881d-45a4-ba29-968ff56614bd